PART I We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimers disease, or AD; Friedreichs ataxia, or FA; Parkinsons disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of our programs are derived from our TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsi...
Q2 FY2026 — expected 2026-09-04
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001104659-26-025197 | EDGAR | 124K words |
| 2025-03-11 | 2024-12-31 | 0001558370-25-002703 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0001558370-24-001988 | EDGAR | — |
| 2023-03-07 | 2022-12-31 | 0001558370-23-002989 | EDGAR | — |
| 2022-03-08 | 2021-12-31 | 0001558370-22-003015 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001558370-21-001865 | EDGAR | — |
| 2020-03-03 | 2019-12-31 | 0001558370-20-001974 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001558370-19-001105 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001558370-18-002038 | EDGAR | — |
| 2017-03-15 | 2016-12-31 | 0001558370-17-001797 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001104659-25-108846 | EDGAR | 23K words |
| 2025-08-06 | 2025-06-30 | 0001558370-25-010511 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001558370-25-006484 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001558370-24-015304 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-011073 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001558370-24-007953 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001558370-23-017754 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001558370-23-013058 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001558370-23-008656 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016733 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012267 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0001558370-22-007065 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-09 | 0001104659-26-025201 | EDGAR | 3K words |
| 2026-02-12 | 0001104659-26-013897 | EDGAR | — |
| 2026-01-08 | 0001104659-26-001955 | EDGAR | — |
| 2025-11-10 | 0001104659-25-108841 | EDGAR | — |
| 2025-09-02 | 0001104659-25-085977 | EDGAR | — |
| 2025-08-06 | 0001558370-25-010507 | EDGAR | — |
| 2025-06-05 | 0001104659-25-056835 | EDGAR | — |
| 2025-05-06 | 0001558370-25-006482 | EDGAR | — |
| 2025-03-11 | 0001558370-25-002702 | EDGAR | — |
| 2025-02-11 | 0001104659-25-011155 | EDGAR | — |
172 total filings indexed. 140 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001640266 |
| Ticker | VYGR |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.voyagertherapeutics.com |
| Listed | 2015-11-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report